Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 18Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 1Leukemia 1

Interventions

nilotinib 5venetoclax 3midostaurin 3ponatinib 2navitoclax 2gilteritinib 2fludarabine phosphate 2asparaginase erwinia chrysanthemi recombinant 2tisagenlecleucel 1revumenib 1pirtobrutinib 1magrolimab 1ivosidenib 1immunotoxin HA22 1idelalisib 1ibrutinib 1glucarpidase 1fludarabine 1eryaspase 1enasidenib 1cc-486 1brexucabtagene autoleucel 1asciminib 1Whole-Body Irradiation 1Transplantation 1Tacrolimus 1Rituximab 1Mycophenolic Acid 1Immunotherapy, Adoptive 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × revumenib × Other hematologic neoplasm × Clear all
NCT05918913 2025-09-05

Expanded Access Program for Revumenib

Syndax Pharmaceuticals

No longer available
1 FDA
Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡